ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences
-
Leerink Partners 6th Annual Global Healthcare ConferenceFebruary 15, 2017 at1:00pm ET -
2017
RBC Capital Markets Global Healthcare Conference February 23, 2017 at9:30am ET -
Cowen and Company 37th AnnualHealth Care Conference March 7, 2017 at8:40am ET
The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen
ImmunoGen is a clinical-stage biotechnology
company that develops targeted cancer therapeutics using its proprietary
antibody-drug conjugate technology. ImmunoGen's lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for folate receptor
alpha (FRα)-positive platinum-resistant ovarian cancer, and is in
Phase 1b/2 testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®,
in three other clinical-stage ImmunoGen product candidates, and in
programs in development by partners Amgen, Bayer, Biotest, CytomX,
Lilly, Novartis, Sanofi and Takeda. More information about the Company
can be found at www.immunogen.com.
Kadcyla® is a registered trademark of
View source version on businesswire.com: http://www.businesswire.com/news/home/20170202006257/en/
Investor Contact:
sarah.kiely@immunogen.com
or
Media
Contacts:
amy.reilly@immunogen.com
or
FTI
Consulting Inc.
Robert Stanislaro, 212-850-5657
robert.stanislaro@fticonsulting.com
Source:
News Provided by Acquire Media